Skip to content
value.today

Checkmate Pharmaceuticals, Inc.

Total raised
$175 M
5 rounds on record
Latest round
$85 M
Jun 2020
First round on record
Aug 2015
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Checkmate Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2020$85 MNo. 5$50 to $250 million

Checkmate Pharmaceuticals, Inc.: Raise no. 5, Jun 2020

Investors in this round

17 investors had bought by the notice of Jun 18, 2020: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Checkmate Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$85 M of $100 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arthur Krieg · Executive Officer, Director
  • Barry Labinger · Executive Officer, Director
  • Charles Yon · Executive Officer
  • James Wooldridge · Executive Officer
  • Jonathan Lieber · Executive Officer
  • Karen Brennan · Executive Officer
  • Kleem Chaudhary · Executive Officer
  • Alan Fuhrman · Director
  • Corey Goodman · Director
  • Keith Flaherty · Director
  • Michael Powell · Director
  • Peter Colabuono · Director
  • Robert Weisskoff · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “$10,083,787 from conversion of promissory notes”

Signed by Barry Labinger, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 18, 2020. Read the notice at the SEC.

equitySEC
Aug 2019$16 MNo. 4$10 to $50 million

Checkmate Pharmaceuticals, Inc.: Raise no. 4, Aug 2019

Investors in this round

4 investors had bought by the notice of Jan 28, 2020: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Checkmate Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arthur Krieg · Executive Officer, Director
  • Barry Labinger · Executive Officer, Director
  • Charles Yon · Executive Officer
  • James Wooldridge · Executive Officer
  • Jonathan Lieber · Executive Officer
  • Karen Brennan · Executive Officer
  • Kleem Chaudhary · Executive Officer
  • Alan Fuhrman · Director
  • Corey Goodman · Director
  • Keith Flaherty · Director
  • Michael Powell · Director
  • Peter Colabuono · Director
  • Robert Weisskoff · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Barry Labinger, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jan 28, 2020. Read the notice at the SEC.

equitySEC
Nov 2018$22 MNo. 3$10 to $50 million

Checkmate Pharmaceuticals, Inc.: Raise no. 3, Nov 2018

Investors in this round

4 investors had bought by the notice of Apr 1, 2019: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Checkmate Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Art Krieg · Executive Officer, Director
  • Barry Labinger · Executive Officer, Director
  • Charles Yon · Executive Officer
  • Chuck Abdalian · Executive Officer
  • David Mauro · Executive Officer
  • Karen Brennan · Executive Officer
  • Ben Auspitz · Director
  • Corey Goodman · Director
  • Michael Powell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Chuck Abdalian, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Apr 1, 2019. Read the notice at the SEC.

equitySEC
Jun 2017$27 MNo. 2$10 to $50 million

Checkmate Pharmaceuticals, Inc.: Raise no. 2, Jun 2017

Investors in this round

3 investors had bought by the notice of Jun 16, 2017: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Checkmate Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$27 M of $27 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arthur M. Krieg · Executive Officer, Director
  • Charles M. Abdalian · Executive Officer
  • Charles M. Yon · Executive Officer
  • David M. Mauro · Executive Officer
  • Ramani M. Varanasi · Executive Officer
  • Ben M. Auspitz · Director
  • Corey M. Goodman · Director
  • Michael M. Powell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Chuck Abdalian, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 16, 2017. Read the notice at the SEC.

equitySEC
Aug 2015$25 MNo. 1$10 to $50 million

Checkmate Pharmaceuticals, Inc.: Raise no. 1, Aug 2015

Investors in this round

2 investors had bought by the notice of Feb 16, 2017: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Checkmate Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arthur A. Krieg · Executive Officer, Director
  • Chuck A. Abdalian · Executive Officer
  • Corey A. Goodman · Director
  • Michael A. Powell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Chuck Abdalian, Chief Financial Officer. Source: SEC Form D and 2 amendments, newest notice filed Feb 16, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Checkmate Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).

    SEC Form D · Jun 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2020

That is all the official record says: Checkmate Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: its website did not answer.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Checkmate Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Novo Holdings A/sFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Sofinnova Management IX, L.L.C.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Sofinnova Venture Partners IX, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
venBio Global Strategic Fund II L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
venBio Global Strategic GP II, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
venBio Global Strategic GP II, Ltd.Companynot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 17 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Checkmate Pharmaceuticals, Inc.
NameRoleNamed in
Arthur KriegExecutive officerJun 2020
Barry LabingerExecutive officerJun 2020
Charles YonExecutive officerJun 2020
James WooldridgeExecutive officerJun 2020
Jonathan LieberExecutive officerJun 2020
Karen BrennanExecutive officerJun 2020
Kleem ChaudharyExecutive officerJun 2020
Jon LieberExecutive officerAug 2019
Art KriegExecutive officerApr 2019
Chuck AbdalianExecutive officerApr 2019
David MauroExecutive officerApr 2019
Arthur M. KriegExecutive officerJun 2017
Charles M. AbdalianExecutive officerJun 2017
Charles M. YonExecutive officerJun 2017
David M. MauroExecutive officerJun 2017
Ramani M. VaranasiExecutive officerJun 2017
Arthur A. KriegExecutive officerFeb 2017
Chuck A. AbdalianExecutive officerFeb 2017
Alan FuhrmanDirectorJun 2020
Arthur KriegDirectorJun 2020
Barry LabingerDirectorJun 2020
Corey GoodmanDirectorJun 2020
Keith FlahertyDirectorJun 2020
Michael PowellDirectorJun 2020
Peter ColabuonoDirectorJun 2020
Robert WeisskoffDirectorJun 2020
Ben AuspitzDirectorAug 2019
Art KriegDirectorApr 2019
Arthur M. KriegDirectorJun 2017
Ben M. AuspitzDirectorJun 2017
Corey M. GoodmanDirectorJun 2017
Michael M. PowellDirectorJun 2017
Arthur A. KriegDirectorFeb 2017
Corey A. GoodmanDirectorFeb 2017
Michael A. PowellDirectorFeb 2017

About

Biopharmaceutical company.